Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Bai, P., Li, Y., Zhou, Q., Xia, J., Wei, P.C., Deng, H., Wu, M., Chan, S.K., Kappler, J.W., Zhou, Y., Tran, E., Marrack, P., Yin, L.(2021) Oncoimmunology 10: 1868130-1868130
- PubMed: 33537173 
- DOI: 10.1080/2162402X.2020.1868130
- Primary Citation of Related Structures:  
6JQ2, 6JQ3, 6JTP, 6JTN - PubMed Abstract: 
Genetic mutations lead to the production of mutated proteins from which peptides are presented to T cells as cancer neoantigens. Evidence suggests that T cells that target neoantigens are the main mediators of effective cancer immunotherapies. Although a ...